Logo image of ILMN

ILLUMINA INC (ILMN) Stock Price, Forecast & Analysis

USA - NASDAQ:ILMN - US4523271090 - Common Stock

121.98 USD
-0.62 (-0.51%)
Last: 11/12/2025, 3:42:31 PM
121.98 USD
0 (0%)
After Hours: 11/12/2025, 3:42:31 PM

ILMN Key Statistics, Chart & Performance

Key Statistics
Market Cap18.75B
Revenue(TTM)4.29B
Net Income(TTM)1.26B
Shares153.70M
Float153.39M
52 Week High153.06
52 Week Low68.7
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)4.36
PE27.98
Fwd PE24.12
Earnings (Next)02-04 2026-02-04/amc
IPO2000-06-28
Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences


ILMN short term performance overview.The bars show the price performance of ILMN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30 40

ILMN long term performance overview.The bars show the price performance of ILMN in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 -40

The current stock price of ILMN is 121.98 USD. In the past month the price increased by 34.73%. In the past year, price decreased by -9.22%.

ILLUMINA INC / ILMN Daily stock chart

ILMN Latest News, Press Relases and Analysis

ILMN Competitors/Peers

The largest stocks on the US markets in the "Life Sciences Tools & Services" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
TMO THERMO FISHER SCIENTIFIC INC 26.25 222.04B
DHR DANAHER CORP 28.46 157.10B
BRKRP BRUKER CORP - BRKR 6 3/8 09/01/28 167.64 50.87B
A AGILENT TECHNOLOGIES INC 27.8 42.96B
IQV IQVIA HOLDINGS INC 18.99 37.55B
MTD METTLER-TOLEDO INTERNATIONAL 34.6 29.82B
WAT WATERS CORP 30.5 23.06B
WST WEST PHARMACEUTICAL SERVICES 38.73 19.69B
MEDP MEDPACE HOLDINGS INC 41.79 16.79B
TEM TEMPUS AI INC N/A 12.35B
RVTY REVVITY INC 19.65 10.93B
TECH BIO-TECHNE CORP 31.81 9.56B

About ILMN

Company Profile

ILMN logo image Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company is headquartered in San Diego, California and currently employs 8,970 full-time employees. The company went IPO on 2000-06-28. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.

Company Info

ILLUMINA INC

5200 Illumina Way

San Diego CALIFORNIA 92122 US

CEO: Francis A. deSouza

Employees: 9000

ILMN Company Website

ILMN Investor Relations

Phone: 18582024500

ILLUMINA INC / ILMN FAQ

Can you describe the business of ILLUMINA INC?

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company is headquartered in San Diego, California and currently employs 8,970 full-time employees. The company went IPO on 2000-06-28. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.


What is the current price of ILMN stock?

The current stock price of ILMN is 121.98 USD. The price decreased by -0.51% in the last trading session.


Does ILLUMINA INC pay dividends?

ILMN does not pay a dividend.


What is the ChartMill rating of ILLUMINA INC stock?

ILMN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Which stock exchange lists ILMN stock?

ILMN stock is listed on the Nasdaq exchange.


What is the ownership structure of ILLUMINA INC (ILMN)?

You can find the ownership structure of ILLUMINA INC (ILMN) on the Ownership tab.


ILMN Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to ILMN. When comparing the yearly performance of all stocks, ILMN turns out to be only a medium performer in the overall market: it outperformed 61.3% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ILMN Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to ILMN. While ILMN belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ILMN Financial Highlights

Over the last trailing twelve months ILMN reported a non-GAAP Earnings per Share(EPS) of 4.36. The EPS increased by 152.02% compared to the year before.


Industry RankSector Rank
PM (TTM) 29.37%
ROA 20.67%
ROE 55.71%
Debt/Equity 0.66
Chartmill High Growth Momentum
EPS Q2Q%17.54%
Sales Q2Q%0.37%
EPS 1Y (TTM)152.02%
Revenue 1Y (TTM)-2.32%

ILMN Forecast & Estimates

28 analysts have analysed ILMN and the average price target is 114.15 USD. This implies a price decrease of -6.42% is expected in the next year compared to the current price of 121.98.

For the next year, analysts expect an EPS growth of 93.48% and a revenue growth -1.07% for ILMN


Analysts
Analysts72.86
Price Target114.15 (-6.42%)
EPS Next Y93.48%
Revenue Next Year-1.07%

ILMN Ownership

Ownership
Inst Owners102.96%
Ins Owners0.18%
Short Float %4.35%
Short Ratio4.36